Deborah J. G. Mackay

Deborah J. G. Mackay

Auto-generated profile, based on publicly available information

Deborah J. G. Mackay

Faculty of Medicine, University of Southampton, Southampton, UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2004 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
AGAnna Gloyn
Anna Gloyn
EPEwan R. Pearson
Ewan R. Pearson
JAJennifer F. Antcliff
Jennifer F. Antcliff
PPPeter Proks
Peter Proks
GBG. Jan Bruining
G. Jan Bruining
AHAndrew T. Hattersley
Andrew T. Hattersley
Patients with permanent neonatal diabetes usually present within the first three months of life and require insulin treatment. In most, the cause is unknown. Because ATP-sensitive potassium (KATP) channels mediate glucose-stimulated insulin secretion from the pancreatic beta cells, we hypothesized that activating mutations in the gene encoding the Kir6.2 subunit of this channel (KCNJ11) cause neonatal diabetes.

29 January 2018 in Nature Reviews Endocrinology
Verified
Journal Article
Open access
PDF file
FBFrédéric Brioude
Frédéric Brioude
JKJennifer M. Kalish
Jennifer M. Kalish
AMAlessandro Mussa
Alessandro Mussa
AFAlison C. Foster
Alison C. Foster
JBJet Bliek
Jet Bliek
EMEamonn R. Maher
Eamonn R. Maher
Beckwith–Wiedemann syndrome (BWS), a human genomic imprinting disorder, is characterized by phenotypic variability that might include overgrowth, macroglossia, abdominal wall defects, neonatal hypoglycaemia, lateralized overgrowth and predisposition to embryonal tumours. Delineation of the molecular defects within the imprinted 11p15.5 region can predict familial recurrence risks and the risk (and type) of embryonal tumour. Despite recent advances in knowledge, there is marked heterogeneity in clinical diagnostic criteria and care. As detailed in this Consensus Statement, an international consensus group agreed upon 72 recommendations for the clinical and molecular diagnosis and management of BWS, including comprehensive protocols for the molecular investigation, care and treatment of patients from the prenatal period to adulthood. The consensus recommendations apply to patients with Beckwith–Wiedemann spectrum (BWSp), covering classical BWS without a molecular diagnosis and BWS-related phenotypes with an 11p15.5 molecular anomaly. Although the consensus group recommends a tumour surveillance programme targeted by molecular subgroups, surveillance might differ according to the local health-care system (for example, in the United States), and the results of targeted and universal surveillance should be evaluated prospectively. International collaboration, including a prospective audit of the results of implementing these consensus recommendations, is required to expand the evidence base for the design of optimum care pathways.

1 August 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
DMDeborah J. G. Mackay
Deborah J. G. Mackay
AHAlan Hall
Alan Hall
The mammalian Rho GTPase family currently consists of seven distinct proteins: Rho (A, B, and C isoforms), Rac (1 and 2 isoforms), Cdc42 (Cdc42Hs and G25K isoforms), RhoD, RhoG, RhoE, and TC10. Like other members of the Ras superfamily, Rho proteins act as molecular switches to control cellular processes by cycling between active, GTP-bound and inactive, GDPbound states (Fig. 1). Activation of the GTPase, through GDP-GTP exchange, is promoted by guanine nucleotide exchange factors (GEFs), 1 whereas inactivation (by an intrinsic GTPase activity) is stimulated by GTPase-activating proteins (GAPs). Rho guanine nucleotide dissociation inhibitors (Rho-GDIs) appear to stabilize the inactive, GDP-bound form of the protein. Activated Rho GTPases interact with cellular target proteins or effectors to trigger a wide variety of cellular responses, including the reorganization of the actin cytoskeleton and changes in gene transcription. This review aims to summarize current views of Rho GTPase signaling pathways; for reasons of space, however, this will be limited primarily to mammalian Rho, Rac, and Cdc42. More detailed information can be found elsewhere (1, 2).

11 July 2008 in Nature Genetics
Verified
Journal Article
Closed access
DMDeborah J G Mackay
Deborah J G Mackay
JCJonathan L A Callaway
Jonathan L A Callaway
SMSophie M Marks
Sophie M Marks
HWHelen E White
Helen E White
CACarlo L Acerini
Carlo L Acerini
ITI Karen Temple
I Karen Temple

2 September 2016 in Nature Reviews Endocrinology
Verified
Journal Article
Open access
PDF file
EWEmma L. Wakeling
Emma L. Wakeling
FBFrédéric Brioude
Frédéric Brioude
OLOluwakemi Lokulo-Sodipe
Oluwakemi Lokulo-Sodipe
SOSusan M. O'Connell
Susan M. O'Connell
JSJennifer Salem
Jennifer Salem
INIrène NETCHINE
Irène NETCHINE
This Consensus Statement summarizes recommendations for clinical diagnosis, investigation and management of patients with Silver–Russell syndrome (SRS), an imprinting disorder that causes prenatal and postnatal growth retardation. Considerable overlap exists between the care of individuals born small for gestational age and those with SRS. However, many specific management issues exist and evidence from controlled trials remains limited. SRS is primarily a clinical diagnosis; however, molecular testing enables confirmation of the clinical diagnosis and defines the subtype. A 'normal' result from a molecular test does not exclude the diagnosis of SRS. The management of children with SRS requires an experienced, multidisciplinary approach. Specific issues include growth failure, severe feeding difficulties, gastrointestinal problems, hypoglycaemia, body asymmetry, scoliosis, motor and speech delay and psychosocial challenges. An early emphasis on adequate nutritional status is important, with awareness that rapid postnatal weight gain might lead to subsequent increased risk of metabolic disorders. The benefits of treating patients with SRS with growth hormone include improved body composition, motor development and appetite, reduced risk of hypoglycaemia and increased height. Clinicians should be aware of possible premature adrenarche, fairly early and rapid central puberty and insulin resistance. Treatment with gonadotropin-releasing hormone analogues can delay progression of central puberty and preserve adult height potential. Long-term follow up is essential to determine the natural history and optimal management in adulthood.

15 January 2019 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
DMDavid Monk
David Monk
DMDeborah J. G. Mackay
Deborah J. G. Mackay
TEThomas Eggermann
Thomas Eggermann
EMEamonn R. Maher
Eamonn R. Maher
ARAndrea Riccio
Andrea Riccio